The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma

摘要: The prognosis of diffuse large B-cell lymphoma (DLBCL) has improved markedly in recent years rituximab era. de novo CD5-positive DLBCL is reported to be poor, but the effect on this type remains unclear. To investigate DLBCL, we collected patients and analysed prognostic factors. A total 157 with who were immunophenotyped flow-cytometry (FCM) treated chemotherapy subjected analysis. Those radiotherapy alone or supportive therapy only not included. Patients diagnosed 2003 later combined chemotherapy. There 95 males 62 females. Their age ranged from 20 91 old, median was 65 years. Nineteen as having DLBCL. Rituximab given alongside 85 patients. Of these, 11 positive for CD5 74 negative. addition overall survival (OS) (2-year OS: 82% vs. 70%, p = 0.01). For CD5-negative showed 2-year OS 84%, which significantly better than those without (70%, 0.008). However, statistically different between (59% 50%, 0.72). Although such improvement restricted group. Further investigation required improve